Cyclophosphamide (CTX)

DRUG16 trials

Sponsors

M.D. Anderson Cancer Center, Vanderbilt-Ingram Cancer Center, Asahi Kasei Pharma Corporation, PharmaMar, Institute of Hematology & Blood Diseases Hospital, China

Conditions

AMLAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, Relapsed, AdultAdvanced Solid TumorsBreast CancerChronic Myeloid Leukemia - Accelerated PhaseDiffuse Large B-cell Lymphoma

Phase 1

R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

RecruitingNCT06594640

Institute of Hematology & Blood Diseases Hospital, ChinaDiffuse Large B-cell Lymphoma

Start: 2024-05-30End: 2027-07-30Target: 108Updated: 2025-05-14

A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors

RecruitingNCT06773091

Shanghai NK Cell Technology Co., LTDAdvanced Solid Tumors

Start: 2025-02-07End: 2026-12-31Target: 76Updated: 2025-02-11

Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell Transplantation

RecruitingNCT06809699

He HuangHematologic Diseases

Start: 2022-08-04End: 2027-10-31Target: 29Updated: 2025-02-05

Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation

RecruitingNCT06809712

He HuangHematologic Disease

Start: 2022-08-04End: 2027-10-31Target: 29Updated: 2025-02-05

Allogeneic CD7 CAR γδ T Cells Therapy Recurrent/Refractory Leukemia

Not yet recruitingNCT07120607

Anhui Provincial HospitalLeukemia

Start: 2025-08-18End: 2027-12-31Target: 9Updated: 2025-08-13

QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS)

Not yet recruitingNCT07131085

Anhui Provincial HospitalAML, MDS

Start: 2025-08-15End: 2027-12-31Target: 9Updated: 2025-08-20

Phase 2

Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia

CompletedNCT00671658

M.D. Anderson Cancer CenterAcute Lymphoblastic Leukemia, Leukemia

Start: 2002-11-30End: 2013-07-31Updated: 2020-12-03

Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage

CompletedNCT00890656

M.D. Anderson Cancer CenterAcute Lymphoblastic Leukemia

Start: 2003-06-30End: 2011-01-31Updated: 2012-02-20

Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)

RecruitingNCT06802315

University of Illinois at ChicagoAcute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, Relapsed, Adult, Chronic Myeloid Leukemia - Accelerated Phase +1

Start: 2025-02-04End: 2032-03-31Target: 38Updated: 2025-06-25

Prostate Cryoablation Combined With Metronomic Cyclophosphamide for Metastatic Prostate Cancer

RecruitingNCT06854250

Sun Yat-sen UniversityMetastatic Prostate Cancer

Start: 2025-03-01End: 2030-03-01Target: 104Updated: 2026-01-13

Phase 3

Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer

CompletedNCT00002836

M.D. Anderson Cancer CenterBreast Cancer

Start: 1995-09-26End: 2006-03-09Updated: 2018-11-06

A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis

CompletedNCT02256150

Asahi Kasei Pharma CorporationLupus Nephritis

Start: 2014-11-30End: 2019-03-31Updated: 2019-06-07

A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome

CompletedNCT02257697

Asahi Kasei Pharma CorporationNephrotic Syndrome

Start: 2014-11-30End: 2018-11-30Updated: 2019-01-17

Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer

CompletedNCT02566993

PharmaMarSmall-cell Lung Cancer

Start: 2016-08-30End: 2020-02-24Updated: 2021-10-28

Unknown Phase

Non-Myeloablative Conditioning and Bone Marrow Transplantation

Active, not recruitingNCT01850108

Vanderbilt-Ingram Cancer CenterHemoglobinopathies, Sickle Cell Disease

Start: 2013-05-31End: 2024-12-31Updated: 2024-01-10

Rapid dFLC Response Predict CHR in AL Amyloidosis

RecruitingNCT06627309

Peking University People's HospitalSystemic AL Amyloidosis

Start: 2024-10-26End: 2026-12-31Target: 50Updated: 2026-03-09

Related Papers

Mizoribine or Cyclophosphamide for Lupus Nephritis

JAMA Network Open2025-03-142 citations

Deciding between Multiple Curative Options in Sickle Cell Disease: Cost-Effectiveness of Non-Myeloablative/Reduced Intensity Conditioning Haploidentical Allo-HSCT Vs Gene Therapy Vs Standard of Care in Adult Patients with Sickle Cell Disease

Blood2024-11-05

An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease

Blood2024-03-1728 citations

A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer.

2024-02-134 citations

Excellent Outcomes of HLA Matched Related Donor Transplant for Adults with Severe Sickle Cell Disease Using a Non-Myeloablative Conditioning with Thiotepa and Post-Transplant Cyclophosphamide: Multi-Center International Experience

Blood2023-11-023 citations

Cerebral hemodynamic changes after haploidentical hematopoietic stem cell transplant in adults with sickle cell disease

Blood Advances2023-10-266 citations

Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLC.

Journal of Clinical Oncology2023-06-011 citations

Safety analysis of lurbinectedin versus topotecan in elderly patients.

Journal of Clinical Oncology2023-06-01

Efficacy and Safety of Mizoribine for the Treatment of Refractory Nephrotic Syndrome: Protocol for a Multicenter, Controlled, Open-label, Randomized Controlled Trial

JMIR Research Protocols2023-03-292 citations

Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2)

Blood2022-11-156 citations

Early Donor T-Cell Engraftment Is Critical for Immune Tolerance in Reduced Intensity Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2)

Blood2022-11-15

Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.

2022-10-1477 citations

Analysis of patients with relapsed small cell lung cancer (SCLC) receiving single-agent lurbinectedin in the phase 3 ATLANTIS trial.

Journal of Clinical Oncology2022-06-016 citations

Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Severe Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC2)

Blood2020-11-054 citations

Transfusion Support in Patients with Sickle Cell Anemia Undergoing Haploidentical Hematopoietic Cell Transplantation

Blood2019-11-13

ATLANTIS: A Phase III Study of Lurbinectedin/Doxorubicin Versus Topotecan or Cyclophosphamide/Doxorubicin/Vincristine in Patients with Small-Cell Lung Cancer Who Have Failed one Prior Platinum-Containing Line

Future Oncology2018-10-2682 citations

ATLANTIS: Global, randomized phase III study of lurbinectedin (L) with doxorubicin (DOX) vs<i>.</i> CAV or topotecan (T) in small-cell lung cancer after platinum therapy.

Journal of Clinical Oncology2018-05-204 citations